.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ09_Danicopan.Danicopan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ09_Danicopan.Danicopan| name: | Danicopan | |
| ATC code: | L04AJ09 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 60 | L |
| clearance: | 6 | L/h |
| other parameters in model implementation | ||
Danicopan is an orally administered, selective oral factor D inhibitor developed as a complement pathway inhibitor, primarily for use in paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. It is not approved by the FDA or EMA as of 2024 but has been investigated in clinical trials for PNH, including as add-on therapy to C5 inhibitors for patients with extravascular hemolysis.
Pharmacokinetic parameters estimated based on phase I and II clinical trial publications and limited publicly available data regarding healthy adult subjects after oral administration.